PAVmed Inc. (PAVM) News
Follow PAVmed Inc. (PAVM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
LUCD PAVM - Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
LUCD PAVM - Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
NEWS | Sep 22, 2026, 11:55 AM UTC
M
PAVmed launches $9.4 million at-the-market offering with A.G.P.
PAVmed entered into a Sales Agreement with A.G.P./Alliance Global Partners to conduct an at-the-market equity offering of up to $9.4 million of common stock. The agent will receive a 3.0% commission on aggregate gross sa
EQUITY | Sep 10, 2026, 10:03 AM UTC
L
PAVmed maintained at Buy by Ascendiant Capital
Ascendiant Capital maintained a Buy rating on PAVmed.
EQUITY | Aug 27, 2026, 11:51 AM UTC
L
Lucid Diagnostics reports Q2 2026 financial results; provides business update
Lucid Diagnostics (PAVM) provides a business update and reports second quarter 2026 financial results, with no additional figures or catalysts included in the feed.
EARNINGS | Aug 13, 2026, 12:01 PM UTC
M
Lucid Diagnostics Secures Coverage For EsoGuard Test
Lucid Diagnostics gets commercial coverage for esophageal DNA test
EQUITY | Aug 05, 2026, 12:47 PM UTC
L
PAVmed Holds Q2 Update Call
PAVmed schedules Q2 business update call
EQUITY | Jul 31, 2026, 12:30 PM UTC
L
Lucid: Holds Q2 Business Update Call
Lucid Diagnostics holds Q2 update call
EQUITY | Jul 30, 2026, 12:31 PM UTC
L
PAVmed trading halted, volatility trading pause
PAVmed trading halted, volatility trading pause
EQUITY | Jul 16, 2026, 01:42 PM UTC